CJC-1295
CJC-1295 is a synthetic analog of Growth Hormone–Releasing Hormone (GHRH) engineered to extend the duration and stability of native GHRH signaling. By acting on pituitary somatotrophs, it promotes physiologic pulses of growth hormone (GH) that subsequently induce hepatic insulin-like growth factor-1 (IGF-1) synthesis. Two principal research variants exist: with DAC (Drug Affinity Complex) and without DAC (Mod GRF(1–29)), each investigated in preclinical systems for GH/IGF-1 regulation, metabolic signaling, connective-tissue remodeling, and circadian hormone rhythm modeling.
Select Dosage
Purchase Options
Bulk Discounts
The information provided is for educational and informational purposes only and should not be interpreted as medical advice. All products described herein are intended strictly for laboratory and research use. They are not approved for human or veterinary administration, and should only be handled by qualified professionals in controlled research environments. Any clinical research must be conducted under the supervision and approval of an Institutional Review Board (IRB), and all preclinical studies must adhere to Institutional Animal Care and Use Committee (IACUC) guidelines in accordance with the Animal Welfare Act (AWA). Users are encouraged to conduct their own due diligence, referencing trusted scientific sources and verifying all information independently before making any purchasing or experimental decisions.
⚠️ Notice: All products are sold for laboratory and research purposes only. They are not intended for diagnostic, therapeutic, or personal use under any circumstances.
CJC-1295
Overview
CJC-1295 is a synthetic analog of Growth Hormone–Releasing Hormone (GHRH) engineered to extend the duration and stability of native GHRH signaling. By acting on pituitary somatotrophs, it promotes physiologic pulses of growth hormone (GH) that subsequently induce hepatic insulin-like growth factor-1 (IGF-1) synthesis. Two principal research variants exist: with DAC (Drug Affinity Complex) and without DAC (Mod GRF(1–29)), each investigated in preclinical systems for GH/IGF-1 regulation, metabolic signaling, connective-tissue remodeling, and circadian hormone rhythm modeling.
Variants
- CJC-1295 with DAC (Drug Affinity Complex): a long-acting conjugate that binds to plasma albumin, extending circulation time to approximately 6–8 days.
- CJC-1295 without DAC (Mod GRF(1–29)): a short-acting analog designed to reproduce natural GH pulsatility, with a half-life of minutes to roughly one hour.
Mechanistic Insights
- Activates GHRH receptors on anterior pituitary somatotrophs, stimulating cAMP/PKA signaling that drives GH synthesis and release.
- DAC modification confers albumin binding, slowing renal clearance and proteolytic degradation; the non-DAC form mirrors native GHRH kinetics to produce transient GH bursts.
Key Research Findings / Observations
CJC-1295 with DAC (Long-Acting Analog)
- Sustained GH/IGF-1 activity observed following DAC-linked analog administration; extended receptor engagement maintained physiologic GH pulse architecture (Teichman 2006; Jetté 2005).
- Enhanced plasma stability and resistance to enzymatic degradation via albumin binding; stable IGF-1 output in controlled pharmacokinetic models.
- Metabolic effects associated with lipolytic enzyme expression in rodent models; connective-tissue remodeling signatures upregulated in preclinical injury contexts.
- Circadian and sleep-phase signaling modeled to sustain rhythmic GH availability.
- Synergistic GH release with ghrelin-pathway secretagogues reported in preclinical pharmacology experiments; preclinical tolerability generally favorable.
CJC-1295 without DAC (Mod GRF(1–29); Short-Acting)
- Supports pulsatile GH dynamics with short half-life, enabling modeling of natural GHRH burst patterns (Achermann 1999).
- Experimental flexibility for aligning GH release with metabolic stress or recovery windows; associated increases in IGF-1 mRNA and myogenic markers in preclinical studies.
- Modulation of lipid-oxidation genes and protein-sparing markers reported in animal research; amplified GH responses when combined with ghrelin-receptor agonists (Massoud 1996).
- Used in neuroendocrine modeling to investigate circadian feedback mechanisms; minimal systemic toxicity reported in preclinical dosing.
Comparative Overview
- Sustained GH/IGF-1 with infrequent dosing:CJC-1295 with DAC — extended half-life and prolonged receptor engagement.
- Modeling natural GH pulsatility: CJC-1295 without DAC — mirrors native GHRH release cycles.
- Dual-pathway GH experiments: Both variants — DAC form supports baseline tone; non-DAC form enables rhythmic co-stimulation.
Research References
- Teichman S.L. et al. (2006). J Clin Endocrinol Metab 91(3): 799–805.
- Jetté L. et al. (2005). Peptides.
- Achermann J.C. et al. (1999). Clin Endocrinol (Oxf).
- Bowers C.Y. et al. (1990). J Clin Endocrinol Metab 70: 975–982.
- Massoud A.F. et al. (1996, 1997). Clin Endocrinol (Oxf).
- Kopchick J.J. et al. (2019). Nat Rev Endocrinol 15: 206–221.
- Giustina A., Veldhuis J.D. (1998). Endocr Rev.
- Thorner M.O. et al. (1997). J Clin Endocrinol Metab.
Product Specifications
C₁₅₂H₂₅₂N₄₄O₄₂
3367.9 g/mol
863288-34-0
DAC:GRF(1-29); Modified Growth Hormone Releasing Factor (1-29)
Lyophilized powder
Keep refrigerated upon reconstitution
Soluble in sterile water and 0.9% NaCl solution
Research-use only. All information summarizes preclinical and in-vitro studies and is not intended for diagnostic, therapeutic, or personal use.
Frequently Asked Questions
Get answers to common questions about CJC-1295 and our research peptides.
Have Questions About CJC-1295?
Get in touch with our research team for detailed information and support.